Odenike O - Search Results

1

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Hoff FW, et al. Among authors: odenike o. Blood Adv. 2024 Oct 22;8(20):5297-5305. doi: 10.1182/bloodadvances.2024013685. Blood Adv. 2024. PMID: 39110987 Free PMC article.

2

Beyond JAK inhibitor therapy in myelofibrosis.

Odenike O. Odenike O. Hematology Am Soc Hematol Educ Program. 2013;2013:545-52. doi: 10.1182/asheducation-2013.1.545. Hematology Am Soc Hematol Educ Program. 2013. PMID: 24319230 Review.

3

The dawn of the molecular era of the myelodysplastic syndromes.

Odenike O, Le Beau MM. Odenike O, et al. N Engl J Med. 2011 Jun 30;364(26):2545-6. doi: 10.1056/NEJMe1102921. N Engl J Med. 2011. PMID: 21714652 No abstract available.

4

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.

Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Verstovsek S, et al. Among authors: odenike o. J Hematol Oncol. 2016 Dec 8;9(1):137. doi: 10.1186/s13045-016-0367-x. J Hematol Oncol. 2016. PMID: 27931243 Free PMC article. Clinical Trial.

5

Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.

Odenike O, Onida F, Padron E. Odenike O, et al. Am Soc Clin Oncol Educ Book. 2015:e398-412. doi: 10.14694/EdBook_AM.2015.35.e398. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993202 Free article. Review.

6

Novel Therapies for Myelofibrosis.

Pettit K, Odenike O. Pettit K, et al. Among authors: odenike o. Curr Hematol Malig Rep. 2017 Dec;12(6):611-624. doi: 10.1007/s11899-017-0403-0. Curr Hematol Malig Rep. 2017. PMID: 29098608 Free PMC article. Review.

7

Myelodysplastic syndromes.

Odenike O, Anastasi J, Le Beau MM. Odenike O, et al. Clin Lab Med. 2011 Dec;31(4):763-84. doi: 10.1016/j.cll.2011.08.005. Epub 2011 Oct 10. Clin Lab Med. 2011. PMID: 22118747 Free PMC article. Review.

8

Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity.

van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz AS. van Besien K, et al. Among authors: odenike o. Leuk Lymphoma. 2012 Jan;53(1):158-9. doi: 10.3109/10428194.2011.604756. Epub 2011 Sep 6. Leuk Lymphoma. 2012. PMID: 21749304 No abstract available.

9

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.

Tallarico M, Odenike O. Tallarico M, et al. Among authors: odenike o. Curr Hematol Malig Rep. 2015 Jun;10(2):112-7. doi: 10.1007/s11899-015-0259-0. Curr Hematol Malig Rep. 2015. PMID: 25893311 Review.

10

Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.

Pettit K, Odenike O. Pettit K, et al. Among authors: odenike o. Expert Rev Hematol. 2016 Sep;9(9):851-859. doi: 10.1080/17474086.2016.1210004. Epub 2016 Jul 29. Expert Rev Hematol. 2016. PMID: 27385032 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters